BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ozay EI, Vijayaraghavan J, Gonzalez-Perez G, Shanthalingam S, Sherman HL, Garrigan DT Jr, Chandiran K, Torres JA, Osborne BA, Tew GN, Slukvin II, Macdonald RA, Kelly K, Minter LM. Cymerus™ iPSC-MSCs significantly prolong survival in a pre-clinical, humanized mouse model of Graft-vs-host disease. Stem Cell Res 2019;35:101401. [PMID: 30738321 DOI: 10.1016/j.scr.2019.101401] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
Number Citing Articles
1 Romanazzo S, Kopecky C, Jiang S, Doshi R, Mukund V, Srivastava P, Rnjak-Kovacina J, Kelly K, Kilian KA. Biomaterials directed activation of a cryostable therapeutic secretome in induced pluripotent stem cell derived mesenchymal stromal cells. J Tissue Eng Regen Med 2022. [PMID: 36017672 DOI: 10.1002/term.3347] [Reference Citation Analysis]
2 Gao S, Zhang Y, Liang K, Bi R, Du Y, Baiocchi M. Mesenchymal Stem Cells (MSCs): A Novel Therapy for Type 2 Diabetes. Stem Cells International 2022;2022:1-17. [DOI: 10.1155/2022/8637493] [Reference Citation Analysis]
3 Wei Y, Wang B, Jia L, Huang W, Xiang AP, Fang C, Liang X, Li W. Lateral Mesoderm-Derived Mesenchymal Stem Cells With Robust Osteochondrogenic Potential and Hematopoiesis-Supporting Ability. Front Mol Biosci 2022;9:767536. [DOI: 10.3389/fmolb.2022.767536] [Reference Citation Analysis]
4 Li Y, Hao J, Hu Z, Yang YG, Zhou Q, Sun L, Wu J. Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review. Stem Cell Res Ther 2022;13:93. [PMID: 35246235 DOI: 10.1186/s13287-022-02751-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
5 Liu TM. Application of mesenchymal stem cells derived from human pluripotent stem cells in regenerative medicine. World J Stem Cells 2021; 13(12): 1826-1844 [DOI: 10.4252/wjsc.v13.i12.1826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Liu X, Robbins S, Wang X, Virk S, Schuck K, Deveza LA, Oo WM, Carmichael K, Antony B, Eckstein F, Wirth W, Little C, Linklater J, Harris A, Humphries D, O'Connell R, Heller G, Buttel T, Lohmander S, Ding C, Hunter DJ. Efficacy and cost-effectiveness of Stem Cell injections for symptomatic relief and strUctural improvement in people with Tibiofemoral knee OsteoaRthritis: protocol for a randomised placebo-controlled trial (the SCUlpTOR trial). BMJ Open 2021;11:e056382. [PMID: 34845081 DOI: 10.1136/bmjopen-2021-056382] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Kelly K, Rasko JEJ. Mesenchymal Stromal Cells for the Treatment of Graft Versus Host Disease. Front Immunol 2021;12:761616. [PMID: 34764962 DOI: 10.3389/fimmu.2021.761616] [Reference Citation Analysis]
8 Colter J, Murari K, Biernaskie J, Kallos MS. Induced pluripotency in the context of stem cell expansion bioprocess development, optimization, and manufacturing: a roadmap to the clinic. NPJ Regen Med 2021;6:72. [PMID: 34725374 DOI: 10.1038/s41536-021-00183-7] [Reference Citation Analysis]
9 Zhang J, Chen M, Liao J, Chang C, Liu Y, Padhiar AA, Zhou Y, Zhou G. Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Hold Lower Heterogeneity and Great Promise in Biological Research and Clinical Applications. Front Cell Dev Biol 2021;9:716907. [PMID: 34660579 DOI: 10.3389/fcell.2021.716907] [Reference Citation Analysis]
10 Wruck W, Graffmann N, Spitzhorn LS, Adjaye J. Human Induced Pluripotent Stem Cell-Derived Mesenchymal Stem Cells Acquire Rejuvenation and Reduced Heterogeneity. Front Cell Dev Biol 2021;9:717772. [PMID: 34604216 DOI: 10.3389/fcell.2021.717772] [Reference Citation Analysis]
11 Thavapalachandran S, Le TYL, Romanazzo S, Rashid FN, Ogawa M, Kilian KA, Brown P, Pouliopoulos J, Barry AM, Fahmy P, Kelly K, Kizana E, Chong JJH. Pluripotent stem cell-derived mesenchymal stromal cells improve cardiac function and vascularity after myocardial infarction. Cytotherapy 2021;23:1074-84. [PMID: 34588150 DOI: 10.1016/j.jcyt.2021.07.016] [Reference Citation Analysis]
12 Kim JY, Nam Y, Rim YA, Ju JH. Review of the Current Trends in Clinical Trials Involving Induced Pluripotent Stem Cells. Stem Cell Rev Rep 2021. [PMID: 34532844 DOI: 10.1007/s12015-021-10262-3] [Reference Citation Analysis]
13 Johnson J, Shojaee M, Mitchell Crow J, Khanabdali R. From Mesenchymal Stromal Cells to Engineered Extracellular Vesicles: A New Therapeutic Paradigm. Front Cell Dev Biol 2021;9:705676. [PMID: 34409037 DOI: 10.3389/fcell.2021.705676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Borziak K, Parvanova I, Finkelstein J. ReMeDy: a platform for integrating and sharing published stem cell research data with a focus on iPSC trials. Database (Oxford) 2021;2021:baab038. [PMID: 34156448 DOI: 10.1093/database/baab038] [Reference Citation Analysis]
15 Spellicy SE, Hess DC. The Immunomodulatory Capacity of Induced Pluripotent Stem Cells in the Post-stroke Environment. Front Cell Dev Biol 2021;9:647415. [PMID: 33796535 DOI: 10.3389/fcell.2021.647415] [Reference Citation Analysis]
16 Nozaki T, Takahashi M, Ishikawa T, Haino A, Seki M, Kikuchi H, Yuan B, Nashimoto M. The heptamer sgRNA targeting the human OCT4 mRNA can upregulate the OCT4 expression. Biochem Biophys Rep 2021;26:100918. [PMID: 33553691 DOI: 10.1016/j.bbrep.2021.100918] [Reference Citation Analysis]
17 Lin Y, Ren X, Chen Y, Chen D. Interaction Between Mesenchymal Stem Cells and Retinal Degenerative Microenvironment. Front Neurosci 2020;14:617377. [PMID: 33551729 DOI: 10.3389/fnins.2020.617377] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Burnham AJ, Foppiani EM, Horwitz EM. Key Metabolic Pathways in MSC-Mediated Immunomodulation: Implications for the Prophylaxis and Treatment of Graft Versus Host Disease. Front Immunol 2020;11:609277. [PMID: 33365034 DOI: 10.3389/fimmu.2020.609277] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Ji W, Hou B, Lin W, Wang L, Zheng W, Li W, Zheng J, Wen X, He P. 3D Bioprinting a human iPSC-derived MSC-loaded scaffold for repair of the uterine endometrium. Acta Biomater 2020;116:268-84. [PMID: 32911103 DOI: 10.1016/j.actbio.2020.09.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
20 Okano H, Sipp D. New trends in cellular therapy. Development 2020;147:dev192567. [PMID: 32943426 DOI: 10.1242/dev.192567] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
21 Bloor AJC, Patel A, Griffin JE, Gilleece MH, Radia R, Yeung DT, Drier D, Larson LS, Uenishi GI, Hei D, Kelly K, Slukvin I, Rasko JEJ. Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study. Nat Med 2020;26:1720-5. [PMID: 32929265 DOI: 10.1038/s41591-020-1050-x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 19.5] [Reference Citation Analysis]
22 Levy O, Kuai R, Siren EMJ, Bhere D, Milton Y, Nissar N, De Biasio M, Heinelt M, Reeve B, Abdi R, Alturki M, Fallatah M, Almalik A, Alhasan AH, Shah K, Karp JM. Shattering barriers toward clinically meaningful MSC therapies. Sci Adv 2020;6:eaba6884. [PMID: 32832666 DOI: 10.1126/sciadv.aba6884] [Cited by in Crossref: 58] [Cited by in F6Publishing: 153] [Article Influence: 29.0] [Reference Citation Analysis]
23 De la Torre-Tarazona HE, Jiménez R, Bueno P, Camarero S, Román L, Fernández-García JL, Beltrán M, Nothias LF, Cachet X, Paolini J, Litaudon M, Alcami J, Bedoya LM. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat. Biochem Pharmacol 2020;177:113937. [PMID: 32224142 DOI: 10.1016/j.bcp.2020.113937] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Romanazzo S, Lin K, Srivastava P, Kilian KA. Targeting cell plasticity for regeneration: From in vitro to in vivo reprogramming. Adv Drug Deliv Rev 2020;161-162:124-44. [PMID: 32822682 DOI: 10.1016/j.addr.2020.08.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
25 Ortuño-Costela MDC, Cerrada V, García-López M, Gallardo ME. The Challenge of Bringing iPSCs to the Patient. Int J Mol Sci 2019;20:E6305. [PMID: 31847153 DOI: 10.3390/ijms20246305] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]